speaking quarter. and welcome, everyone. be with again you this Robert, Thank I'm pleased you, to
to and prescription successfully our ADHD positive fiscal returned quarter, we pediatric During the sequential second growth. both portfolios
in first which late sequential 'XX. portfolios since both such exhibited growth occurrence The
addressable I'll in coverage we on broadened distribution trends a benefits this physician our navigating and drive more touch job improvement sales ADHD our with doing to landscape and the of a macro done various payer in for RxConnect also and market team increasing first-in-class demand commercial leverage the while as dispensing. continuing dynamics both markets And we're the platform. has moment. our our of Aytu Our Pediatric great team
commercial operating to efficiencies in recently cost with $X driving million at momentum optimization million future we This expected $X our corporate runs is within positive annually. parallel announced structure initiatives, in in cost savings our This result health savings spending, the operations. years, to undergone addition significant already operations of consumer OpEx have X the realizing a discontinuing exiting transformation our last our and reductions pipeline pausing of in we we're manufacturing as the inclusive least
of profitable the focus touch also pursuing leveraging forward as more that commercial Our Aytu the additional and acquired in our unique products, going is RxConnect platform, capabilities our momentarily. on business or well on I'll while prescription in-licensed infrastructure
full Even remain cash savings business adjusted realization consecutive we quarter optimization Xnd we consecutive track the before of And our quarter flows. of positive to takes EBITDA net income. the hold, of drive Xth positive reported to on our and
was up the which and quarter In the from told, the outlook of All million, during the end slightly the progress the with was continued pleased rest for September. cash year. second fact, very at million of balance December $XX.X the end our of made $XX.X at I'm fiscal
ADHD. each into and areas, of the our for outlook with numbers, trends jump Let's portfolio script starting
[ year. top 'XX $XX QX From in perspective, over portfolio which XX,XXX XX,XXX, a For million under to compared quarter, of compared net in revenue last in ] to scripts just quarter the first for were was the line But XXX,XXX fiscal QX slightly we had compares the I million into QX ADHD ADHD revenue $XX.X in and want detail the we million net revenue. great went of last again the during highlights out apples-to-apples commercial We boosted basis. in on improvement this quarter and discussing quarter once QX saw as compared an to year. net call re-pickup this to ADHD $XX.X it last to that
a quarter $X onetime a resulted revenue million last recall, with sheet rebates on for quarter, [ rebate that ] in balance quarter resolved that We our a we during likely we of prior multiyear on which first our unauthorized have liability periods revenue previously resolved for gross in commercial past over dispute been few As and and net net years. a a to payer products, had resolution been have net in last reduction increase of our you'll the carrying we the which reduced the and ADHD accrual. carrying
you out scripts $XX.X The revenue would compares favorably net approximately from in recorded million. have been $XX.X million XX,XXX ADHD $X.X QX's million million XX,XXX in $XX.X scripts revenue very revenue, net on If about on back just with QX in also we net QX.
sequentially So be an This item. onetime year. is net, improvement on actually calendar highlights our heading into our exclude model basis, script sequentially. expected per net ADHD given was in final gross increased to apples-to-apples the to XX% somewhat of revenue which net the up business a an our price quarter
Adel of broadly stimulant the commencing in and ] other a significant 'XX ADHD that supply market-wide of conditions at to market, meds. more ADHD the more normalized [ following we like and see state Looking Xr the early stimulant stimulant products to continue returning impacted series shortages
never long-term facing. and As I've shortages fortunately, we, were the realize impacted others discussed, benefits some and from therefore, Aytu short-term supply was
ago, trends mentioned ago are has many With made a we the the a moved to Adzenys years levels basis. positive from over the difficult year-over-year few once normalized, bit base comps above benefit short-term we stayed or quite patients the the as as term. a on a longer are market Cotempla were had more sequential moment that just has and on again But I
transition Pediatric I'll over portfolio. to the now
Pediatric covering payer impact has market affecting saw the a few we This was communicated we've entire had a class. last payer we exacerbated this further fairly where quarters, multivitamin some payer within of impacted a the As dispensing concentrated of stop by large the for changes. Pediatrics, portion as we big of variety areas multivitamins share. large Initially, were a
Our where concentration a with Medicaid. by prescribers significant product of had payer covered an change antihistamine that was area we by in similarly largely a affected pretty
bringing diversifying focused our in base Medicaid been Fast on payer and antihistamine focused several the coverage areas plans dispensing improving franchise. franchises, expanding as forward, base that our pharmacies prescriber well we've we with we've for promotion, [indiscernible] before. state as of In both particular, multivitamins products of had and on diversifying on
more that are X [ With much for force's penetration emphasis benefits commercial sales We've all these we more the products. this products improved increased so in our of promoting last product shifted across eggs that to having sales or and conducted the coverage specifically impactful also and the better resources Previously, the today coverage much started our to were access proverbial mix, and with with and X balance our on group and that, really force. We've products. for smaller in to X of a with our of ], is materially Pediatric the our brands. are covering on product and public states realize has that Pediatric focused providing largely Pediatric opposed many representatives just specialists this Pediatric deployed as first occurred sales now months. the or improvement shifted sales better sales quarter X products, of baskets, So we over
you seeing trends. saw and Rx we're the by revenue in very As release, encouraged and are press net already dividends latest our
the when a and this [ good look rate XX% annualized sequentially and promotional was increase up base our QX, I'm we strategies: continuing to last portfolio a quarters improve current with key [indiscernible] Pediatric years X products sales again positive you few coverage, yet over ] implement these pleased not We're as at the of script we prescribers revenue were for net run where the force. with the and During trends increased We're but X materially. $XX momentum diversify footprint ago, scripts as on the quarter. see diversify to
pay me and leverage that apart the remain More us flagship go significant our to to and Indulge we the a ecosystem moment it's best-in-class soapbox access a competition one In hop and is to environment, to pharmaceutical broadly, platform, stand on my prescriber health a to just believe from Healthcare today's differentiator on a for patients. company care as a here. RxConnect, better for simply truly solution. Aytu and company we benefit focused which enables offer not enough continuing clinical
the solve pharmacies solve impact problem patient, payer of the clinical and to entire which, the You've have to but you course, patients, access challenges, absolutely pervasive the benefits, for alike. for physicians got includes
get to if going CVS can get they're received timely have or were form a price case they're into and going in in it, it frankly, pay might walk the they going and whether pay, when co-pay, be what the today Walgreens, can to all-in to Patients it no Walmart they're product if neighborhood, idea manner prescribed, and whatever to out-the-door the is be. that's whether a that comes cash an of whether cash or paying they a when
transparency reduces to Its is predictable Aytu. U.S. to The top-to-bottom a The caps pharmacy the in-house market that confidence proprietary cash This comes prescription RxConnect so patient patients Reimbursement affordable, value-add get and very ultimately that's ] [ soup and opaque. at price. dispensing and speak, hassles their System in. to and here that developed and Aytu to lacks the where program nuts, an Distribution we've at Pharmaceutical protects is branded allows outlays prescriber, provides consistency,
deliver a in established network serve of recognized that and small They're an well well hard work for work country. job around RxConnect geographies pharmacies often of go excellent for patients that the above in do are and with levels whom involves, are X,XXX beyond these very high pharmacies businesses about independent things, to other and patients. and Most prescribers among the well respective patients service and of and local communities. we
very of and to chains them work more excellent The our make of customer-centric, is service our and stocking products us other are directly with regional X to provide network grocery available. part that adequate
to, them when products, up one get the send insured commercially exceed is and we their So everything sell these they $XX physicians parts prescriptions which covered, will offer including pharmacies, benefits $X. benefits for they a to tell as from obviously RxConnect that on co-pay, patients a our way, if the that these sell standpoint, mentioned, they will then we include are of the patients clinical equal to partner when often not and co-pay, of by full the
This much the may is there where prevent a covered or obtain thus in or help [indiscernible] cases in partners authorization step underwrite [indiscernible]. at and and prior foremost, is authorization, in access. physicians prior the they the prescription a also that's a product off price the that helps it's can okay, the cases a were burden on even prescribed as taking their know there's We patient where It patient helps that that physicians of prescription not And time. prescribed our first and get predictable getting that affordable.
routinely, are take many rest for life. potentially these to that products your month going reminder, after of a month the As you're for many, years,
where opaque you can month, patients. next it a and issue So it very today than make designed And price your for this walk challenging you have way it to solves into and PBMs paid be that's different may this significant the month, pay to you chain pharmacy.
even back that through beyond don't was a saying or means. with pharmacy our a co-pay brands way was all of what patient We ridiculous, it can't crazy that fear freed get it, the my or prescribe to parent saying cut so have high expected have that. RxConnect, I from we dreaded worse, calling of of up the we without either physicians beyond callback And we
we're with we And the And alike. power believe succeed. the and the for have for patients. at time stakeholders we physicians of for first every for And the back Aytu, is why and to with For working success day. RXConnect, what achieve prescribers, pharmacies single RXConnect, hands us, put that's the we winning into these can prescribing patients that's for
program is what future look be has like. the And in the future ADHD to to the that products Aytu our into a The products really stay Aytu enables of these Pediatric develops game our and RXConnect think to franchise, this dovetails key changer we we the our the ability of as differentiator franchise part. will look
need positive as we note, of containment of to our that and the on continued and of long organic initiatives mid goal look towards goal term, the with flows. cash and we ADHD foremost On driving portfolios, at growth first our and Pediatric cost the focus
that maybe understanding that transactions. organization have fit growth, at nonstrategic. we shown history, we has assets that series expect also our adept yet are that, Beyond strategic valuable a become Aytu and a at of been inorganic particular identifying smallest built we through have don't Throughout
capabilities to see to in-licensing portfolio we opportunity and or tremendous these. So by our like leverage assets diversify acquiring and our infrastructure expertise
course, and possible. as Of pick these look about to we'll assets be as it attractively smart up
now, our goal allow not-too-distant to at revenue further infrastructure. base the continue our larger generate And is for commercial assets low in bolt For flows, within commercial the then future our on incrementally leverage hopefully, this free cash we area to opportunities smallish fit the as our the that can start also that cost. and appetite look tuck-in we to high-performing footprint well. is in to in bolster and we to can portfolio, as Ultimately, continue diversify us
review the closing Let we comments, turn financials questions. me details, more provide which your the to a few now can and in Ryan? Ryan after I'll to over take call
